As of 2026-05-05, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.9x - 13.8x | 13.2x |
| Forward P/E multiples | 12.5x - 17.6x | 15.6x |
| Fair Price | (162.93) - (181.73) | (189.48) |
| Upside | -825.1% - -908.8% | -943.2% |
| Date | EV/EBITDA |